Dose response of ACE inhibitors: implications of the SECURE trial by Lonn, Eva
ACE = angiotensin-converting enzyme; ATLAS = Assessment of Treatment with Lisinopril and Survival trial; CAD = coronary artery disease; HOPE
= Heart Outcomes Prevention Evaluation study; LV = left ventricular; NETWORK trial = Network of general practitioners and hospital physicians
involved in the study of low versus high doses of enalapril in patients with heart failure trial; NYHA = New York Heart Association; SECURE = Study
to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and Vitamin E; QUIET = Quinapril Ischemic Event Trial.
Available online http://cvm.controlled-trials.com/content/2/4/155
Angiotensin-converting enzyme (ACE) inhibitors have
been used extensively in the management of hypertension
and heart failure. Recent trials, primarily the Heart Out-
comes Prevention Evaluation (HOPE) study, also demon-
strate a clear role for these agents in reducing the risk for
adverse cardiovascular outcomes in patients without heart
failure and with preserved left ventricular (LV) ejection
fraction [1]. Experimental research and recent clinical
studies also show favorable effects of ACE inhibitor
therapy on the arterial vascular wall. The Study to Evaluate
Carotid Ultrasound changes in patients treated with
Ramipril and vitamin E (SECURE), a substudy of the
HOPE trial, thus demonstrated reduced progression of
carotid atherosclerosis in patients treated with ramipril [2].
Other investigations have revealed improved endothelial
function in patients receiving ACE inhibitors [3,4].
What are ‘optimal’ doses of ACE inhibitors to be used in
different clinical settings? This question is encountered
frequently by clinicians and remains controversial. A
number of surveys suggest that clinicians often prefer the
use of low doses of ACE inhibitors, and the perception
that low doses are as effective as high ones is quite preva-
lent. In addition, clinicians frequently titrate ACE inhibitor
dose according to blood pressure and rely on ‘adequate’
blood pressure control as a marker of the effectiveness of
this therapy, not only in patients treated for hypertension,
but also in those treated for heart failure and for reduction
of cardiovascular risk.
In this commentary, several lines of evidence have been
extracted from clinical trials in chronic heart failure, coro-
nary artery disease (CAD) and atherosclerosis to show
that the size of the ACE inhibitor dose matters, higher
doses are more effective than lower doses and the dura-
tion of therapy is important.
Clinical trials comparing high and low doses
of ACE inhibitors in chronic heart failure
Several clinical trials in heart failure have specifically
addressed the question of optimal ACE inhibitor dose
(Table 1) [5–8]. With the exception of the Assessment of
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Abstract
The choice of the appropriate dosage of ACE inhibitor in clinical practice is an important one. The
available evidence suggests that in chronic heart failure as well as in chronic coronary artery disease,
high doses of angiotensin-converting enzyme (ACE) inhibitor are more effective than low ones. The
current recommended clinical approach is to target ACE inhibitor dosing regimens to be similar to
those used in the clinical trials, which demonstrated mortality and morbidity benefits. When titrated
appropriately, ACE inhibitors are generally well tolerated and target doses can be achieved and
maintained in the majority of patients with atherosclerotic vascular disease, with or without heart failure.
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Treatment with Lisinopril and Survival (ATLAS) trial, these
studies have been underpowered, both with regard to the
number of patients studied and the duration of treatment
and follow-up. Furthermore, some of these studies, such as
the Network of General Practitioners and Hospital Physi-
cians Involved in the Study of Low versus High Doses of
Enalapril in Patients with Heart Failure (NETWORK) trial
(which found no conclusive benefit for higher versus lower
dose enalapril) enrolled mainly patients with mild, New York
Heart Association (NYHA) class I heart failure. The ATLAS
trial, a much larger study with adequate long-term follow-up
lasting 46 months, enrolled a significant proportion (84%)
of patients with more advanced, class III or IV NYHA heart
failure symptoms. This study identified a significant 12%
lower risk for death or all-cause hospitalization and a 24%
reduction in hospitalizations for heart failure in patients
treated with high-dose compared to those treated with low-
dose lisinopril. The extended analysis of the ATLAS study,
including patients at high risk for cardiovascular death
(such as diabetics and those with LV ejection fraction of
less than 25%), showed similar benefit in the combined
endpoint of mortality and all-cause hospital admissions.
These findings support the use of higher doses of ACE
inhibitors in patients with chronic heart failure [9]. ‘Very
high’ ACE inhibitor doses (i.e. higher than those usually
employed in clinical practice) are unlikely to provide addi-
tional benefit [8].
A number of prospective observational studies have
reported that heart failure patients discharged from hospi-
tal and maintained on ‘high’ ACE inhibitor doses had
improved clinical outcomes compared to those receiving
low dose therapy. The benefits included lower rates of
death and re-hospitalization, thus incurring lower costs
[10,11]. The ability to achieve adequate doses of ACE
inhibitors for the treatment of chronic heart failure in
general practice is also well documented. Studies such as
the prospective evaluation by Messner Pellenc found that
a daily dose of 20 mg of enalapril could be reached in a
high proportion of heart-failure patients with good tolera-
bility and improved outcomes [12].
Clinical practice guidelines, published by both the Agency
for Health Care Policy and Research and the American
College of Cardiology/American Heart Association, reflect
the findings of these studies. These recommend that when
managing chronic heart failure, every effort should be
made to increase the dose of ACE inhibitors to the target
doses shown in clinical trials to decrease mortality and
morbidity, for example at least 150 mg daily of captopril or
at least 20 mg daily of enalapril or lisinopril [13,14].
ACE inhibitor dose in chronic coronary artery
disease
A number of large randomized controlled clinical trials have
demonstrated the beneficial effects of ACE inhibitors in
coronary artery disease in patients with prior, recent or
remote myocardial infarction [15–19]. Such trials have
enrolled patients either with heart failure or with docu-
mented LV systolic dysfunction and, more recently in the
HOPE trial, patients with preserved LV ejection fraction
without heart failure symptoms. In addition to improved
mortality rates and a reduction in heart-failure-related out-
comes, the major randomized clinical trials of ACE
inhibitors in CAD have also demonstrated a reduction in
acute ischemic events. These large clinical trials have not
compared different ACE inhibitor dosing regimens, but
invariably used ‘high’ target ACE inhibitor doses. Among
these studies, those with longer duration of treatment and
follow-up showed more pronounced benefits (Fig. 1).
Notably, the Quinapril Ischemic Event Trial (QUIET) [20],
used an intermediate dose of quinapril (20 mg daily) and
failed to demonstrate a clear benefit for ACE inhibitor
Table 1
Trials exploring ACE inhibitor dosing regimens in heart failure
Trial ACE-I regimens (daily doses) Major findings
NETWORK (n=1532) Enalapril 2.5 mg bid vs 5 mg bid vs 10 mg bid No difference in hospitalizations for heart failure; trend 
Follow-up: 5.5 months towards fewer deaths with increasing dose
ATLAS (n=3164) Lisinopril 2.5–5 mg od vs 32.5–35 mg od Trends towards reduced total and CV mortality and 
Follow-up:46 months significant reduction in mortality and all-cause 
hospitalizations for high-dose lisinopril
CHIPS (n=298) Captopril 25 mg bid vs 50 mg bid Trend towards reduced hospitalizations for heart failure and 
Follow-up: 2 years towards reduced fatal and nonfatal cardiac events for 
high-dose captopril
HEDS (n=248) Enalapril 20 mg vs 60 mg No significant differences in survival, clinical and 
Follow-up: 12 months hemodynamic variables
ACE-I = angiotensin-converting enzyme inhibitor; ATLAS = Assessment of Treatment with Lisinopril and Survival; CHIPS = Captopril in Heat
Insufficient Patients Study; HEDS = High Enalapril Dose Study; NETWORK = Network of General Practitioners and Hospital Physicians Involved
in the Study of Low versus High Doses of Enalapril in Patients with Heart Failure trial.c
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therapy in patients with preserved LV systolic function. By
contra-distinction, the Trial on Reversing Endothelial Dys-
function (TREND) substudy of QUIET, which used a
higher ACE inhibitor daily dose of 40 mg of quinapril, did
show significant improvement in coronary endothelial func-
tion in actively treated patients. The failure to demonstrate
a statistically significant advantage for quinapril in the
QUIET trial may be related to multiple factors, such as the
low event rates, the inadequate sample size, the duration
of the study and the suboptimal compliance. It remains
possible, however, that the chosen ACE inhibitor dose
may have also contributed to the overall disappointing
results of this study.
In the absence of clinical trials that compare high-dose
versus low-dose ACE inhibitor regimens in chronic CAD,
the most prudent approach is to aim for the relatively high
target doses used in the large randomized clinical trials.
Studies of ACE inhibitors in atherosclerosis
A large body of experimental evidence suggests that pro-
longed ACE inhibitor therapy may have beneficial effects
on atherogenesis, both by inhibiting the formation of tissue
and circulating angiotensin II and by bradykinin potentia-
tion. These ACE inhibitor actions result in decreased pro-
liferation and migration of smooth muscle cells, decreased
accumulation and activation of inflammatory cells,
decreased oxidative stress, and increased endothelial
nitric oxide formation, leading to improved endothelial
function [21]. Increased ACE activity has been demon-
strated in human coronary artery lesions [22], and long-
term ACE inhibitor therapy has been shown to reduce the
area of atherosclerotic lesions in normotensive animal
models of atherosclerosis. Interestingly, in all the experi-
mental animal model studies of atherosclerosis that
demonstrated beneficial effects of ACE inhibitors, high
drug doses were used (e.g. captopril 3–25 mg/kg/day,
cilazapril 10 mg/kg/day, quinapril 10 mg/kg/day) [23–26].
A number of clinical studies have evaluated the effect of
ACE inhibitor therapy on the progression of atherosclero-
sis. The results of these studies are not fully concordant.
The best demonstration of a clear effect of ACE inhibitor
therapy on retarding the anatomic progression of athero-
sclerosis is provided by the SECURE substudy of HOPE.
This study enrolled 732 high-risk patients aged 55 years
or more with vascular disease or diabetes and at least one
other risk factor, but without a history of heart failure or a
low LV ejection fraction. Patients were randomized to
treatment with 2.5 mg ramipril/day, 10 mg ramipril/day, or
a placebo, and the progression of atherosclerosis was
monitored by B-mode carotid ultrasound. There was an
overall benefit associated with the use of ramipril.
Although the study was not powered to compare the two
doses of ramipril, there was a trend suggesting a dose-
dependent effect with the highest benefit for the group on
10 mg ramipril/day (Fig. 2). A dose of 10 mg ramipril/day
was also used in the large parent HOPE trial, where it was
shown to have clear benefits on a range of clinical end-
points. Furthermore, it is notable that blood pressure low-
ering with the two doses of ramipril used in the SECURE
trial did not parallel the effects on atherosclerosis. This
finding confirms that blood pressure is not an adequate
surrogate marker for determining the most effective ACE
inhibitor dose, when treating either patients without hyper-
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Figure 1
The effect of ACE inhibitor therapy on myocardial infarction in chronic
coronary artery disease. ACE inhibitor dose and duration of therapy in
the major large clinical trials of ACE inhibitors in coronary artery
disease are shown. Reduction in myocardial infarction risk was
obtained with prolonged administration of high doses of ACE
inhibitors. AIRE = Acute Infarction Ramipril Efficay study; HOPE =
Heart Outcomes Prevention Evaluation study; SAVE = Survival and
Ventricular Enlargement Trial; SOLVD-P = Studies of Left Ventricular
Enlargement — Prevention arm; SOLVD-T = Studies of Left Ventricular
Enlargement — Treatment arm; TRACE = Trandolapril Cardiac
Evaluation study.
Figure 2
The effect of ramipril on carotid atherosclerosis in the SECURE trial.
There was a dose-dependent benefit with reduction in atherosclerosis
progression attained with ramipril whcih was more effective at the
higher dose of 10 mg/day than in the lower dose of 2.5 mg/day.
P = 0.033 overall ramipril effect. *P = 0.028 for ramipril 10 mg/day
versus placebo. Mean maximum IMT = average of maximum intimal-
medial thickness across 12 predefined carotid arterial segments.tension or hypertensives with baseline, well-controlled
blood pressure. The SECURE trial supports the notion
that the effect on the vascular wall is dependent on dose,
and that higher ACE inhibitor dose regimens are associ-
ated with higher benefit. Recent additional data from the
echocardiographic substudy of the HOPE trial also show
similar dose-dependent beneficial effects of ramipril on LV
mass and function (Table 2) [27].
Conclusions
The choice of ACE inhibitor dose to be used in clinical
practice remains a very important and difficult one.
Although the evidence that is currently available does not
clearly identify the optimal ACE inhibitor dose level to be
used in different clinical settings, it suggests the following:
1. Higher doses of ACE inhibitors are better than lower
doses in chronic heart failure and in coronary artery
disease.
2. Duration of therapy is important. In patients with ather-
osclerotic vascular disease (with or without LV systolic
function and with or without clinical manifestations of
heart failure) prolonged therapy is associated with
improved outcomes.
3. The safest and most logical clinical approach needs to
be based on principles of evidence-based medicine.
The currently available evidence supports the use of
those specific ACE inhibitors shown to reduce mortality
and morbidity in clinical trials. The target doses used in
these clinical trials were 10 mg ramipril/day, 20–40 mg
enalapril/day, 150 mg captopril/day, 10–35 mg lisino-
pril/day or 4 mg trandolapril/day. The use of other ACE
inhibitors that have not been tested in large-scale clini-
cal trials with mortality and/or morbidity endpoints, and
the use of lower target ACE inhibitor doses cannot be
endorsed [28].
4. There are no adequate surrogate markers to aid clini-
cians in the choice of the most effective ACE inhibitor
dose. The use of blood pressure and even the use of
clinical symptoms appear to be inadequate in deter-
mining optimal ACE inhibitor dose level.
5. High ACE inhibitor doses, when titrated appropriately,
are generally well tolerated and can be achieved and
maintained in the majority of patients with atheroscle-
rotic vascular disease and/or chronic heart failure. In
those who cannot tolerate target doses, the highest
tolerated dose should be used.
CAD remains the main killer of men and women in our
society. An aggressive approach to therapy with compre-
hensive risk factor modification and use of multiple drugs
as well as non-pharmaceutical approaches can improve
significantly both quality of life and survival in most
patients. Maximizing doses of drugs that are shown to be
effective is an important component of this aggressive
treatment strategy and should be applied rigorously.
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